More than 15% of individuals living with HIV and cancer have not received recommended first-line cancer therapy, according to results of a retrospective analysis.Among patients with HIV and cancer, ...

No, Atlanta is not experiencing an outbreak of HIV, although the rates of new diagnosis are considered high in some ...

Despite recent ASCO and FDA guidance recommending the inclusion of people living with HIV in pivotal cancer trials, nearly 75 ...

Central Florida faces one of the highest HIV prevalence rates in the nation, with over 14,000 individuals currently living with the virus. Approximately 13% of those infected are unaware of their ...

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

The US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...

HIV's route to infection is more flexible than previously believed, study finds by Emily Kagey, Morgan Sherburne, University of Michigan edited by Lisa Lock, reviewed by Robert Egan Editors' notes ...

JACKSON, Miss. (WLBT) -A new breakthrough drug for HIV Prevention has been approved by the FDA. The drug is called “Yeztugo” ...

Not everyone knows that gay pageants are not only fodder for internet virality or the butt of a joke, they can also be an ...

The US has approved lenacapavir for HIV prevention. However, experts worry that cuts to the health budget will "squander" the drug's chance of reducing infections.